COVID Drug Maker Tevogen To Go Public Via SPAC At $1.2B
Biotech company Tevogen Bio and Semper Paratus, a special purpose acquisition company, announced an agreement to merge on Thursday, which would take the combined company public at a pro forma enterprise...To view the full article, register now.
Already a subscriber? Click here to view full article